Covidien has received clearance from the U.S. Food and Drug Administration (FDA) for its contrast delivery system with radiofrequency identification (RFID) technology, the company said.
The system combines Covidien's unit-dose Ultraject prefilled contrast media syringes with OptiVantage DH power injectors. RFID is an automatic identification technology that captures, stores, and transmits data between the syringe and the power injector using RFID transponders, allowing radiologic technologists to ensure that the patient is getting the prescribed drug and drug dose during a procedure, according to the Hamilton, Bermuda-based firm.
The company expects to begin marketing the system this summer.
Related Reading
Covidien posts strong Q2, May 7, 2008
Covidien gets tentative nod for generic sestamibi, February 27, 2008
Covidien settles Medrad litigation, February 14, 2008
NRC investigates Covidien production issue, February 8, 2008
Medical sales drive Covidien's Q1 growth, February 7, 2008
Copyright © 2008 AuntMinnie.com
